Publication:
Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study).

dc.contributor.authorSanchez-Torralvo, Francisco Jose
dc.contributor.authorVazquez-Pedreño, Luis
dc.contributor.authorGonzalo-Marin, Montserrat
dc.contributor.authorTapia, Maria Jose
dc.contributor.authorLima, Fuensanta
dc.contributor.authorGarcia-Fuentes, Eduardo
dc.contributor.authorGarcia, Pilar
dc.contributor.authorMoreno-Ruiz, Javier
dc.contributor.authorRodriguez-Cañete, Alberto
dc.contributor.authorValdes, Sergio
dc.contributor.authorOlveira, Gabriel
dc.contributor.funderPlataforma Española de Investigación Clínica y Ensayos Clínicos, SCReN (Spanish Clinical Research Network)
dc.contributor.funderISCIII-Subdirección General de Evaluación y Fomento de la Investigación
dc.contributor.funderPlan Estatal de I+D+I 2013-2016
dc.contributor.funderEuropean Regional Development Fund (ERDF)
dc.date.accessioned2023-05-03T14:06:15Z
dc.date.available2023-05-03T14:06:15Z
dc.date.issued2022-04-11
dc.description.abstractBackground: Intragastric injection of botulinum toxin A (BT-A) has been shown to be effective for weight loss up to six months after administration, according to previous studies. Our objective was to determine, in patients on bariatric surgery waiting lists, the effect of BT-A on weight loss in the pre- and postoperative period and to analyse if there are different responses based on Body Mass Index (BMI). Methods: We performed a follow-up analysis of the IntraTox study, which included 46 patients on bariatric surgery waiting lists in a single-centre, randomised, double-blind, placebo-controlled clinical trial. The treatment group received intragastric BT-A, whereas the control group received physiological saline solution. The one-time procedure was performed at the time of diagnostic endoscopy 7−8 months before surgery. Weight loss was evaluated at admission and after 4 and 12 weeks from the bariatric surgery. Our analysis was stratified by BMI at randomisation. Results: weight loss percentage on the day of surgery, with respect to the initial visit, was −4.5 ± 3.9% for the control group vs. −7.6 ± 4.2%, for the treatment group (p = 0.013). Weight loss percentage tended to remain greater in the treatment group one month after the intervention (−12.7 ± 4.7% vs. −15.2 ± 4.6%, p = 0.07) and become similar three months after (−21.6 ± 4.7% vs. −21.6 ± 4.6%). After stratifying by BMI, only patients with BMI over 50 kg/m2 allocated to the treatment group obtained a greater weight loss at the end of the trial, the day of surgery, and one month after, compared with the placebo group (−4.9 ± 4.9%, −10.8 ± 5.3% and −17.1 ± 3.8% vs. −0.1 ± 2.6%, −4.3 ± 3.2% and −12.8 ± 4.1%, respectively (p< 0.05). Conclusions: intragastric injection of BT-A is effective to achieve significant weight loss, especially in extreme obesity. Its use before bariatric surgery enhances perioperative weight loss.
dc.description.versionSi
dc.identifier.citationSánchez-Torralvo FJ, Vázquez-Pedreño L, Gonzalo-Marín M, Tapia MJ, Lima F, García-Fuentes E, et al. Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study). J Clin Med. 2022 Apr 11;11(8):2126
dc.identifier.doi10.3390/jcm11082126
dc.identifier.issn2077-0383
dc.identifier.pmcPMC9027998
dc.identifier.pmid35456220
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027998/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2077-0383/11/8/2126/pdf?version=1649726637
dc.identifier.urihttp://hdl.handle.net/10668/21268
dc.issue.number8
dc.journal.titleJournal of clinical medicine
dc.journal.titleabbreviationJ Clin Med
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number9
dc.provenanceRealizada la curación de contenido 28/03/2025
dc.publisherMDPI
dc.pubmedtypeJournal Article
dc.relation.projectIDPT13/0002/0020
dc.relation.projectIDPT17/0020
dc.relation.publisherversionhttps://www.mdpi.com/resolver?pii=jcm11082126
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBariatric surgery
dc.subjectBotulinum toxin
dc.subjectEndoscopy
dc.subjectObesity
dc.subjectWeight loss
dc.subject.decsPérdida de Peso
dc.subject.decsCirugía Bariátrica
dc.subject.decsCirugía General
dc.subject.decsInyecciones
dc.subject.decsObesidad
dc.subject.decsToxinas Botulínicas Tipo A
dc.subject.meshSaline Solution
dc.subject.meshWaiting Lists
dc.subject.meshObesity, Morbid
dc.subject.meshBariatric Surgery
dc.subject.meshPostoperative Period
dc.titleEndoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study).
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9027998.pdf
Size:
817.11 KB
Format:
Adobe Portable Document Format